



SmartPA Criteria Proposal

Drug/Drug Class:	Beta Adrenergic Blockers and Beta Adrenergic Blockers/Diuretic Combinations PDL Edit
First Implementation Date:	July 19, 2004
Revised Date:	September 23, 2021
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why was this Issue Selected: Beta-adrenergic blockers inhibit the chronotropic, inotropic and vasodilator responses to adrenaline by blocking β_1 and β_2 receptor sites throughout the body. Several characteristics of beta-blockers may be related to their clinical effectiveness. Beta blockers can be classified by cardioselectivity and intrinsic sympathomimetic activity (ISA). Cardioselective beta-blockers preferentially inhibit only β_1 receptors that are principally found in the myocardium. Non-cardioselective beta blockers inhibit both β_1 and β_2 receptor sites.

Total program savings for the PDL classes will be regularly reviewed.

Program-specific information:

Preferred Agents	Non-Preferred Agents
<ul style="list-style-type: none"> • Acebutolol • Atenolol • Atenolol/Chlorthalidone • Bisoprolol • Bisoprolol/HCTZ • Carvedilol • Hemangeol[®] • Labetalol • Metoprolol Succinate • Metoprolol Tartrate • Metoprolol/HCTZ • Nadolol • Propranolol Soln/Tabs • Propranolol/HCTZ • Sorine[®] • Sotalol • Sotalol AF 	<ul style="list-style-type: none"> • Betapace[®] • Betapace AF[®] • Betaxolol • Bystolic[®] • Carvedilol ER • Coreg[®] • Coreg CR[®] • Corgard[®] • Inderal LA[®] • Inderal XL[®] • InnoPran XL[®] • Kaspargo[®] Sprinkle Caps • Lopressor[®] • Lopressor HCT[®] • Nadolol/Bendroflumethiazide • Nebivolol • Pindolol • Propranolol LA

SmartPA PDL Proposal Form

© 2021 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Default Approval Period

1 year

References

1. Evidence-Based Medicine and Fiscal Analysis: “Beta Adrenergic Blockers and Diuretic Combination Agents – Therapeutic Class Review”, Conduent Business Services, L.L.C., Richmond, VA; July 2021.
2. Evidence-Based Medicine Analysis: “Oral Beta Blockers (and any beta-blocker combinations)”, UMKC-DIC; November 2003 – August 2020.
3. Evidence-Based Medicine Analysis: “Beta Adrenergic Blockers and Diuretic Combinations”, UMKC-DIC; June 2021.
4. USPDI, Micromedex; 2021.
5. Facts and Comparisons eAnswers (online); 2021 Clinical Drug Information, LLC.